about
Zika virus: a new threat to the safety of the blood supply with worldwide impact and implicationsIL-1β signaling promotes CNS-intrinsic immune control of West Nile virus infectionTregs control the development of symptomatic West Nile virus infection in humans and miceMolecular detection of Zika virus in blood and RNA load determination during the French Polynesian outbreakThoughts Around the Zika Virus CrisisAmustaline (S-303) treatment inactivates high levels of Zika virus in red blood cell componentsRelative analytical sensitivity of donor nucleic acid amplification technology screening and diagnostic real-time polymerase chain reaction assays for detection of Zika virus RNAEmergence of Zika virus: where does it come from and where is it going to?Zika virus in Singapore: unanswered questions.Galectin-9 is rapidly released during acute HIV-1 infection and remains sustained at high levels despite viral suppression even in elite controllers.Association between HLA class I and class II alleles and the outcome of West Nile virus infection: an exploratory studyHIV+ elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses.West Nile virus nucleic acid persistence in whole blood months after clearance in plasma: implication for transfusion and transplantation safety.Increased frequency of Tim-3 expressing T cells is associated with symptomatic West Nile virus infection.Soluble T cell immunoglobulin mucin domain 3 is shed from CD8+ T cells by the sheddase ADAM10, is increased in plasma during untreated HIV infection, and correlates with HIV disease progression.Downregulation of Cytokines and Chemokines by GB Virus C After Transmission Via Blood Transfusion in HIV-Positive Blood RecipientsNeuroinvasive West Nile Infection Elicits Elevated and Atypically Polarized T Cell Responses That Promote a Pathogenic Outcome.Dengue in the context of "safe blood" and global epidemiology: to screen or not to screen?Blood group A and D negativity are associated with symptomatic West Nile virus infectionHuman memory T cells with a naive phenotype accumulate with aging and respond to persistent virusesInactivation of Zika virus in platelet components using amotosalen and ultraviolet A illumination.An update on Zika virus infection.Blood Gene Signatures of Chagas Cardiomyopathy With or Without Ventricular Dysfunction.The importance of Foxp3 antibody and fixation/permeabilization buffer combinations in identifying CD4+CD25+Foxp3+ regulatory T cells.[West Nile virus. II. Immunopathophysiology in humans].[West Nile virus - I. conquest of the West].Interferon and interferon-induced chemokine expression is associated with control of acute viremia in West Nile virus-infected blood donors.Comprehensive analysis of west nile virus-specific T cell responses in humans.Pathogen inactivation of Dengue virus in red blood cells using amustaline and glutathione.Zika virus in French Polynesia 2013-14: anatomy of a completed outbreak.Documentation of transfusion-transmitted arbovirus infections in endemic areas.Inactivation of chikungunya virus in blood components treated with amotosalen/ultraviolet A light or amustaline/glutathione.Ethnicity, sex, and age are determinants of red blood cell storage and stress hemolysis: results of the REDS-III RBC-Omics studyIntradonor reproducibility and changes in hemolytic variables during red blood cell storage: results of recall phase of the REDS-III RBC-Omics study
P50
Q24575968-E4D81040-A752-46AA-94FA-99F21272CA62Q27340022-14961524-1932-4F43-BF47-A16E7CA10129Q27490259-F4C7A221-7260-4DCF-B7F9-1962B7D36D58Q27869771-388E582B-767E-4406-97A8-06820AA1CF68Q27927997-BB93BC44-B455-4D35-A7A7-1260CF683289Q28729789-CE141B6E-07D8-4690-8C32-51F490A101B4Q28804144-B977968D-B6A8-43A0-8094-3F875EE7C6CEQ28829835-DE4B27BD-756B-41B4-B83C-8AEF64DBBAC1Q30145586-90899601-2445-4FFB-AA05-FB05511E5A93Q33828349-C6AAD815-9B9B-420E-84DB-CA55817E4367Q33988636-9A7ED740-7569-49B3-B2B7-C0CF6BF5BED1Q34275430-973E7E3F-0F57-41C1-87EB-7384CD486CB9Q34718025-1BF1719F-8D6C-4A85-B63A-8370A1A34DBEQ35123912-B96840FC-088F-495E-A9E1-3D5526AB95B0Q35487768-17C698B1-6547-4A36-83E3-45F8DAC882F2Q35784618-961A8DB8-2FB4-4333-B66A-347C6C6EFEB4Q35900167-39AD0AE6-5428-4C3D-B719-A38DA246CB98Q36433186-0E39531B-02EA-4314-9463-15A4512156BBQ37079789-0DC717A1-2207-49F8-8379-31AD18B8A5A3Q37114301-8F79D009-4CAF-4483-9CE7-648CEF194A72Q38158233-B4CFDE7F-0CB5-4FF2-8D49-4EDDF7DBCD84Q38158525-F517E642-98BA-41B7-996B-C643D08F585BQ39003348-A311EF4D-2F73-45E0-97F9-F2B84E016DD3Q40302787-C0D78377-E1E7-44CE-95D4-3AAA897C0370Q40326867-5DB4F7D6-63D4-4AD1-870F-CD122936AB0CQ40326872-468D0B37-84EB-4335-BF2C-C90372A19B37Q40411174-119F2D89-BF7F-4A3F-ABF4-B7AEA4FEC0B2Q40421352-E29EBC9B-0DE3-4C99-841F-BA55BDD50983Q41935541-E483AEEA-5AC7-4169-BE1B-C437DE4BA92CQ45324658-2165A65E-87A1-48B3-9E24-9F4BB5A41603Q46109599-6B8C683D-73A3-4F5E-8944-FA8FD26D3FCFQ47555572-62DE79FF-9DD0-4257-B0A2-E6B9152A99FFQ56434610-F8B74771-3EF8-4A89-8EE6-D0EB169CD61DQ58590834-11B6620A-4683-4FE1-8747-B1906B2E7DAB
P50
name
Marion C. Lanteri
@ast
Marion C. Lanteri
@en
Marion C. Lanteri
@nl
type
label
Marion C. Lanteri
@ast
Marion C. Lanteri
@en
Marion C. Lanteri
@nl
prefLabel
Marion C. Lanteri
@ast
Marion C. Lanteri
@en
Marion C. Lanteri
@nl